5b2d4661dbf98c0004b12098_1.png
AngioSoma Strengthens IP Position With New Patent Filing
October 16, 2018 06:00 ET | AngioSoma, Inc.
OmniCath™ II Patent Filing Showcases Product Effectiveness Houston, TX, Oct. 16, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading pharmaceutical research and...
5b2d4661dbf98c0004b12098_1.png
New Formula of StemStrength by AngioSoma Inc. Now Available to The Public Online
October 15, 2018 06:00 ET | AngioSoma, Inc.
HOUSTON, TX, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma (OTC: SOAN), a leading biotechnology company, announces today the availability of the anticipated new and improved version...
5b2d4661dbf98c0004b12098_1.png
AngioSoma Unveils New Logo and Brand Identity
July 11, 2018 14:32 ET | AngioSoma, Inc.
Houston, TX., July 11, 2018 (GLOBE NEWSWIRE) -- AngioSoma (OTC: SOAN) today launched a new corporate logo and website, marking the most dramatic change in its visual identity since 2016. Taking a...
5b2d4661dbf98c0004b12098_1.png
AngioSoma Prepares for Final FDA Approval Process on Company's Flagship Biologic
June 25, 2018 09:30 ET | AngioSoma, Inc.
HOUSTON, TX, June 25, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is in discussions to engage a respected pharmaceutical regulatory advisory firm to help it navigate the Food and Drug...
AngioSoma, Inc. Anno
AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug
June 18, 2018 11:44 ET | AngioSoma, Inc.
HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™,...
AngioSoma, Inc. Anno
AngioSoma, Inc. Announces Grant of Patent for Flagship Drug
May 14, 2018 12:13 ET | AngioSoma, Inc.
HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship...